Rilonacept
Template:Short description Template:Short description Page Template:Infobox drug/styles.css has no content.
Page Module:Infobox/styles.css has no content.
Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.[1][2][3] Rilonacept is an interleukin 1 inhibitor.[4]
Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.[5]
Rilonacept was given an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome.[3][6] Rilonacept is the first drug approved by the FDA to treat recurrent pericarditis.[3] Rilonacept was approved for medical use in the United States in February 2008.[7]
On May 8, 2012, an FDA Advisory Panel voted 11–0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[8]
References
Page Template:Reflist/styles.css has no content.
- ^ a b Page Module:Citation/CS1/styles.css has no content."Arcalyst- rilonacept injection, powder, lyophilized, for solution". DailyMed. Retrieved 18 March 2021.
- ^ a b Page Module:Citation/CS1/styles.css has no content."Rilonacept Regeneron (previously Arcalyst) EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 March 2021.
- ^ a b c Page Module:Citation/CS1/styles.css has no content."FDA Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart". U.S. Food and Drug Administration (FDA). 18 March 2021. Archived from the original on March 18, 2021. Retrieved 18 March 2021. Public Domain This article incorporates text from this source, which is in the public domain.
- ^ Page Module:Citation/CS1/styles.css has no content.Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. (October 2009). "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study". Annals of the Rheumatic Diseases. 68 (10): 1613–7. doi:10.1136/ard.2009.108936. PMC 2732898. PMID 19635719.
- ^ Page Module:Citation/CS1/styles.css has no content."Molecule of the month. Rilonacept". Drug News & Perspectives. 21 (4): 232. May 2008. PMID 18560622.
- ^ Page Module:Citation/CS1/styles.css has no content."Arcalyst FDA Approval History - Drugs.com". Archived from the original on 2012-05-16. Retrieved 2012-05-08.
- ^ Page Module:Citation/CS1/styles.css has no content."Drug Approval Package: Arcalyst (Rilonacept) NDA #125249". U.S. Food and Drug Administration (FDA). 2 May 2008. Archived from the original on April 14, 2021. Retrieved 20 March 2021.
- ^ Page Module:Citation/CS1/styles.css has no content."Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". 8 May 2012. Archived from the original on 2012-05-21. Retrieved 2012-05-08.
External links
- Page Module:Citation/CS1/styles.css has no content."Rilonacept". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on January 23, 2017.
Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Interleukin receptor modulators Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
